PURPOSE: To test the efficacy of bronchial artery embolization (BAE) to treat haemoptysis in pulmonary hypertension (PH). METHODS: 33 patients were treated by BAE for haemoptysis associated with PH (PH group = 21) or non-associated with PH (control group = 12). The details of procedure, outcome, and rate of relapse were compared between the two groups. Within the PH group, the comparison was operated between subjects with congenital heart disease-associated pulmonary artery hypertension (CHD-APAH subgroup = 12) and non-CHD (non-CHD-APAH subgroup = 9). RESULTS: The rate of relapse at 30 and 90-days was similar between the PH group and control group. BAE in the PH group was more challenging (median 2 arteries embolized per procedure) compared to the control group (median 1 artery embolized per procedure; p = 0.001). Bleeding arteries were more heterogeneous in the PH group, while a single right bronchial artery was the only clinical finding in 66.7% of controls (p = 0.001). Within the PH group, the CHD subgroup showed higher survival rate compared to the non-CHD-APAH group (p = 0.007). CONCLUSION: BAE is effective and safe for the treatment of haemoptysis in PH, yet more challenging than other conditions. In PH-associated haemoptysis, BAE provides higher survival rate for subjects with PH associated with CHD

Bronchial artery embolization for the treatment of haemoptysis in pulmonary hypertension / Rasciti, Edoardo; Sverzellati, Nicola; Silva, Mario; Casadei, Andrea; Attinà, Domenico; Palazzini, Massimiliano; Galiè, Nazzareno; Zompatori, Maurizio. - In: LA RADIOLOGIA MEDICA. - ISSN 1826-6983. - ELETTRONICO. - 122:4(2017), pp. 257-264. [10.1007/s11547-016-0714-6]

Bronchial artery embolization for the treatment of haemoptysis in pulmonary hypertension

PALAZZINI, MASSIMILIANO;GALIE', NAZZARENO;ZOMPATORI, MAURIZIO
2017

Abstract

PURPOSE: To test the efficacy of bronchial artery embolization (BAE) to treat haemoptysis in pulmonary hypertension (PH). METHODS: 33 patients were treated by BAE for haemoptysis associated with PH (PH group = 21) or non-associated with PH (control group = 12). The details of procedure, outcome, and rate of relapse were compared between the two groups. Within the PH group, the comparison was operated between subjects with congenital heart disease-associated pulmonary artery hypertension (CHD-APAH subgroup = 12) and non-CHD (non-CHD-APAH subgroup = 9). RESULTS: The rate of relapse at 30 and 90-days was similar between the PH group and control group. BAE in the PH group was more challenging (median 2 arteries embolized per procedure) compared to the control group (median 1 artery embolized per procedure; p = 0.001). Bleeding arteries were more heterogeneous in the PH group, while a single right bronchial artery was the only clinical finding in 66.7% of controls (p = 0.001). Within the PH group, the CHD subgroup showed higher survival rate compared to the non-CHD-APAH group (p = 0.007). CONCLUSION: BAE is effective and safe for the treatment of haemoptysis in PH, yet more challenging than other conditions. In PH-associated haemoptysis, BAE provides higher survival rate for subjects with PH associated with CHD
2017
Bronchial artery embolization for the treatment of haemoptysis in pulmonary hypertension / Rasciti, Edoardo; Sverzellati, Nicola; Silva, Mario; Casadei, Andrea; Attinà, Domenico; Palazzini, Massimiliano; Galiè, Nazzareno; Zompatori, Maurizio. - In: LA RADIOLOGIA MEDICA. - ISSN 1826-6983. - ELETTRONICO. - 122:4(2017), pp. 257-264. [10.1007/s11547-016-0714-6]
Rasciti, Edoardo; Sverzellati, Nicola; Silva, Mario; Casadei, Andrea; Attinà, Domenico; Palazzini, Massimiliano; Galiè, Nazzareno; Zompatori, Maurizio
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/574373
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 11
social impact